Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elironrasib and Daraxonrasib in Advanced KRAS G12C-Mutated Solid Tumors
NCT06128551Phase 2Recruiting
- Sponsor
- Revolution Medicines
- Start
- Nov 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 7
01
Overview
A Phase 2 trial of elironrasib, daraxonrasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), solid tumor, sponsored by Revolution Medicines. Started Nov 2023; status: recruiting.
02
Drugs
elironrasibdaraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT06128551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128551.